Shanghai Pharmaceuticals Holding Co., Ltd. Announcement on Holding the 2025 Annual Performance Briefing

Log in to the Sina Finance APP and search for [Information Disclosure] to view more evaluation levels.

Stock Code: 601607 Stock Abbreviation: Shanghai Pharmaceuticals Announcement No.: Lin 2026-019

Shanghai Pharmaceuticals Holding Co., Ltd.

Announcement on the Annual Performance Presentation for 2025

The Board of Directors and all directors of the company guarantee that the content of this announcement does not contain any false records, misleading statements, or major omissions, and bear legal responsibility for the truthfulness, accuracy, and completeness of its content.

Important Content Reminder:

Meeting Time: April 8, 2026 (Wednesday) 10:00-11:00

Meeting Location: Shanghai Stock Exchange Roadshow Center (website:

Meeting Format: Online interaction at the Roadshow Center

Investors can log in to the homepage of the Roadshow Center website from March 31, 2026 (Tuesday) to April 7, 2026 (Tuesday) before 16:00 to submit questions in the “Pre-collection of Questions” section. The company will answer questions that are of general concern to investors during the presentation.

Shanghai Pharmaceuticals Holding Co., Ltd. (hereinafter referred to as “the company”) will release its 2025 annual report after the market closes on March 30, 2026. In order to facilitate a more comprehensive understanding of the company’s 2025 annual operating results and financial status, the company plans to hold an annual performance presentation on April 8, 2026 (Wednesday) from 10:00 to 11:00 to communicate on issues of interest to investors.

1. Type of Presentation

This investor presentation will be conducted in an online interactive format, where the company will engage with investors regarding the specific circumstances of the 2025 annual operating results and financial indicators, and will answer questions that are of general concern to investors within the scope allowed by information disclosure.

2. Time and Location of the Presentation

(1) Meeting Time: April 8, 2026 (Wednesday) 10:00-11:00

(2) Meeting Location: Roadshow Center

(3) Meeting Format: Online interaction at the Roadshow Center

3. Participants

Shen Bo, Executive Director, President

Gu Chaoyang, Independent Director

Zhou Yadong, Vice President, CFO

Zhong Tao, Vice President, Board Secretary

The above participants will be adjusted based on actual circumstances.

4. How Investors Can Participate

(1) Investors can log in to the Roadshow Center on April 8, 2026 (Wednesday) from 10:00 to 11:00 via the internet to participate in this performance presentation, and the company will promptly answer investors’ questions.

(2) Investors can log in to the homepage of the Roadshow Center website from March 31, 2026 (Tuesday) to April 7, 2026 (Tuesday) before 16:00 and click on the “Pre-collection of Questions” section (

5. Contact Person and Consultation Method

Contact Person: Board Office

Phone: 021-63557167

Email: boardoffice@sphchina.com

6. Other Matters

After this investor presentation, investors can check the status and main content of this presentation through the Roadshow Center (

This announcement is hereby made.

Shanghai Pharmaceuticals Holding Co., Ltd.

Board of Directors

March 27, 2026

Stock Code: 601607 Stock Abbreviation: Shanghai Pharmaceuticals Announcement No.: Lin 2026-020

Shanghai Pharmaceuticals Holding Co., Ltd.

Announcement on the Approval for Production of Dihydroxypropyl Theophylline Injection

The Board of Directors and all directors of the company guarantee that the content of this announcement does not contain any false records, misleading statements, or major omissions, and bear individual and joint responsibility for its truthfulness, accuracy, and completeness.

Recently, Shanghai Pharmaceuticals Holding Co., Ltd. (hereinafter referred to as “the company”) announced that its subsidiary Shanghai Hefeng Pharmaceutical Co., Ltd. (hereinafter referred to as “Hefeng”) has received the “Drug Registration Certificate” (Certificate No.: 2026S00781) issued by the National Medical Products Administration (NMPA) for its Dihydroxypropyl Theophylline Injection (hereinafter referred to as “the drug”), which has been approved for production.

1. Basic Information about the Drug

Drug Name: Dihydroxypropyl Theophylline Injection

Dosage Form: Injection

Specification: 2ml: 0.3g

Registration Category: Class 3 Chemical Drug

Drug Approval Number: Guo Yao Zhun Zi H20263655

Applicant: Shanghai Hefeng Pharmaceutical Co., Ltd.

Approval Conclusion: According to the “Drug Administration Law of the People’s Republic of China” and relevant regulations, after examination, this product meets the requirements for drug registration and is approved for registration, and a drug registration certificate is issued.

2. Information Related to the Drug

Dihydroxypropyl Theophylline Injection is indicated for the relief of wheezing symptoms in bronchial asthma, wheezing bronchitis, and obstructive pulmonary emphysema. It can also be used for wheezing due to cardiogenic pulmonary edema.

In October 2024, Hefeng submitted a registration application for this drug to the NMPA, which was accepted. As of the date of this announcement, the company has invested approximately RMB 3.14 million in research and development costs for this drug.

As of the date of this announcement, the main manufacturers of Dihydroxypropyl Theophylline Injection in China include Jilin Jinsheng Pharmaceutical Co., Ltd., Sichuan Miaoji Biotechnology Co., Ltd., Shanxi Taiyuan Pharmaceutical Co., Ltd., and others.

According to the IQVIA database, the amount for Dihydroxypropyl Theophylline Injection purchased by hospitals in mainland China in 2025 is RMB 324.83 million.

3. Impact on the Listed Company and Risk Warning

According to relevant national policies, generic drugs approved under the new registration category will receive greater support in areas such as medical insurance payment and procurement by medical institutions. Therefore, the approval for production of Hefeng’s Dihydroxypropyl Theophylline Injection is beneficial for expanding the market share of this drug, enhancing market competitiveness, and accumulating valuable experience for the company’s subsequent generic drug applications.

Due to uncertainties influenced by national policies, market conditions, and other factors, there may be situations where sales do not meet expectations for this drug, which carries significant uncertainty. Investors are advised to make cautious decisions and pay attention to investment risks.

This announcement is hereby made.

Shanghai Pharmaceuticals Holding Co., Ltd.

Board of Directors

March 27, 2026

Massive information and precise interpretation can be found in the Sina Finance APP.